21 58 310
www.stocktitan.net
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Alps Group (Nasdaq: ALPS) reported fiscal year 2026 revenue of $4.86 million, up 44% from $3.37 million in 2025, driven mainly by medical testing, laboratory and aesthetics services ($3.15 million) and cellular therapy ($0.88 million). The company completed its Business Combination with Globalink in October 2025 and began trading on the Nasdaq Global Market.Gross profit rose to $1.56 million, but gross margin declined to 32% from 39% on revenue mix and profit-sharing in aesthetics. Net loss narrowed to $2.09 million from $2.62 million, while administrative expenses increased to $3.50 million, including $1.16 million of Business Combination professional fees. Cash and cash equivalents increased to $0.61 million, supported by $2.93 million net financing inflows and $2.58 million net operating cash outflows. As of March 31, 2026, Alps reported capital deficiencies of $3.23 million, total liabilities of $10.20 million and negative equity, alongside progress in its NK cell therapy (MyImmune), exosome pipeline and expanded Whole Genome Sequencing accreditation.
